WO2021036814A1 - 吡唑衍生物及其用途 - Google Patents
吡唑衍生物及其用途 Download PDFInfo
- Publication number
- WO2021036814A1 WO2021036814A1 PCT/CN2020/109130 CN2020109130W WO2021036814A1 WO 2021036814 A1 WO2021036814 A1 WO 2021036814A1 CN 2020109130 W CN2020109130 W CN 2020109130W WO 2021036814 A1 WO2021036814 A1 WO 2021036814A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- cancer
- kinase inhibitor
- pdgfr kinase
- Prior art date
Links
- 0 Cc1cccc(*)n1 Chemical compound Cc1cccc(*)n1 0.000 description 4
- JIHFPMOCMHQNGQ-UHFFFAOYSA-N CC(C([n]1nnc(-c2cc(N3CCN(C)CC3)cnc2)c1)=C1)=CCC1NC(c1ccnc(C(F)(F)F)c1)=O Chemical compound CC(C([n]1nnc(-c2cc(N3CCN(C)CC3)cnc2)c1)=C1)=CCC1NC(c1ccnc(C(F)(F)F)c1)=O JIHFPMOCMHQNGQ-UHFFFAOYSA-N 0.000 description 1
- RPJODTDGVKMJHW-UHFFFAOYSA-N Cc(c(-[n]1ncc(C(C=NCC2)=C2OCC2OCCC2)c1)c1)ccc1NC(c1ccnc(C(F)(F)F)c1)=O Chemical compound Cc(c(-[n]1ncc(C(C=NCC2)=C2OCC2OCCC2)c1)c1)ccc1NC(c1ccnc(C(F)(F)F)c1)=O RPJODTDGVKMJHW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- PDGFR ⁇ is similar in structure to PDGFR ⁇ , and can form heterodimers and homodimers.
- PDGF-BB and PDGF-DD are the main activators of ⁇ homodimers.
- PDGF-AA only activates ⁇ receptor dimers, while PDGF-AB, PDGF-BB and PDGF-CC activate ⁇ and ⁇ receptor dimers.
- the dimer ligand molecule binds to two receptor proteins simultaneously, and induces receptor dimerization, autophosphorylation of specific residues in the receptor cytoplasmic domain, and cell signaling.
- the A ring is selected from: R 2 is selected from fluorine, chlorine and trifluoromethyl.
- the present invention provides a selective PDGFR kinase inhibitor, comprising a compound of formula (Ia) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof:
- the present invention also provides methods and uses for the compound or pharmaceutical composition to inhibit the activity of tyrosine kinase (wild type or various mutations or combinations thereof), and the treatment, prevention or improvement of tyrosine kinase ( Wild-type or various mutations or combinations thereof).
- the amino acid kinase may be PDGFR.
- Figure 2a shows the change over time in the survival rate of mice in different treatment groups using compound 1, imatinib, bosentan and vehicle in a rat pulmonary hypertension model
- the present invention uses conventional methods such as mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA technology, and pharmacology within the technical scope of the art.
- mass spectrometry NMR, HPLC, protein chemistry, biochemistry, recombinant DNA technology, and pharmacology
- nomenclature and laboratory operations and techniques related to the analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry described herein are known to those skilled in the art.
- the aforementioned techniques and steps can be implemented by conventional methods well known in the art and described in various general documents and more specific documents, which are cited and discussed in this specification.
- heterocycloalkyl or “heterocyclyl” as used herein means that one or more of the atoms constituting the ring in the non-aromatic ring are heteroatoms selected from nitrogen, oxygen and sulfur.
- the heterocycloalkyl ring may be a monocyclic or polycyclic ring composed of three, four, five, six, seven, eight, nine, or more than nine atoms.
- the heterocycloalkyl ring may be optionally substituted.
- the amino protecting group is preferably selected from the group consisting of pivaloyl, tert-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyl, p-methoxybenzyl, allyloxycarbonyl, trifluoroacetyl, and the like.
- target protein refers to a protein molecule or part of a protein that can be bound by a selective binding compound.
- the target protein is the tyrosine kinase PDGFR (including its wild type or various mutations or combinations thereof).
- Novel kinase inhibitor of the present invention Novel kinase inhibitor of the present invention
- Ring A is a pyridine ring
- R 1 is selected heterocycloalkyl, a heterocyclic group, a heterocyclic C 1-6 alkoxy group, a heterocycloalkyl group, spiro cycloalkyl heteroalkyl, heteroalkyl spiro cycloalkyl group, C 3- 6 cycloalkyl C 1-6 alkoxy, C 3-6 cycloalkyloxy, wherein the heterocycloalkyl group is a 4- to 8-membered oxygen and/or nitrogen atom-containing heterocycloalkyl group, and the The nitrogen atom in heterocycloalkyl is optionally substituted by C 1-6 alkyl;
- R 1 is selected heterocycloalkyl, a heterocyclic group, a heterocyclic C 1-6 alkoxy group, a heterocycloalkyl group, spiro cycloalkyl heteroalkyl, heteroalkyl spiro cycloalkyl group, C 3- 6 cycloalkyl C 1-6 alkoxy, C 3-6 cycloalkyloxy, wherein the heterocycloalkyl is optionally substituted by C 1-6 alkyl;
- the PDGFR kinase inhibitor of the present invention is selected from the following compounds or pharmaceutically acceptable salts thereof:
- other therapeutic agents may also be cytokines such as G-CSF (granulocyte colony stimulating factor).
- other therapeutic agents may also be, for example, but not limited to, CMF (cyclophosphamide, methotrexate and 5-fluorouracil), CAF (cyclophosphamide, adriamycin and 5-fluorouracil), AC (sub- Driamycin and cyclophosphamide), FEC (5-fluorouracil, epirubicin and cyclophosphamide), ACT or ATC (adriamycin, cyclophosphamide and paclitaxel) or CMFP (cyclophosphamide, A Methotrexate, 5-fluorouracil and prednisone).
- CMF cyclophosphamide, methotrexate and 5-fluorouracil
- CAF cyclophosphamide, adriamycin and 5-fluorouracil
- AC sub- Dri
- the starting materials used to synthesize the compounds described herein can be synthesized or can be obtained from commercial sources.
- the compounds described herein and other related compounds with different substituents can be synthesized using techniques and raw materials known to those skilled in the art.
- the general methods for preparing the compounds disclosed herein can be derived from reactions known in the art, and the reactions can be modified by reagents and conditions deemed appropriate by those skilled in the art to introduce various moieties in the molecules provided herein.
- mice were killed by carbon dioxide, the subcutaneous tumors were taken out, and the tumors were weighed and compared;
- the tail artery blood of rats was taken for blood gas analysis.
- 0.5 mL of tail artery blood was slowly drawn, transferred to an anticoagulation tube, and placed in a blood gas analyzer to determine the partial pressure of oxygen in the blood (pO 2 ), carbon dioxide partial pressure (pCO 2 ), blood oxygen saturation (SaO 2 ) indicators, the operation of the instrument is in accordance with the standard operating procedures of blood gas analyzers, and the mice with pulmonary hypertension are randomly grouped according to the measurement results. Each group has 10 rats.
- Rats were divided into: negative control group (vehicle group), 50 mg/kg bosentan group (purchased from Shanghai MCE), a clinical drug for the treatment of pulmonary hypertension, 50 mg/kg imatinib group, 45 mg/kg compound 1, 30 mg/kg compound 1 and 15 mg/kg compound 1.
- Each rat was given intragastric administration on the day of regrouping in the 4th week, once a day, and the negative control group was given an equal volume of methylcellulose solvent per day.
- Each group was given intragastric administration for 4 consecutive weeks, that is, 28 days. Gavage was performed daily while observing the state of each rat in each group to see if there were symptoms such as dyspnea, decreased activity, and accelerated heartbeat. The overnight fasting weight was measured twice a week, and the dosage was calculated based on the weighing result.
- pulmonary artery pressure and right ventricular systolic pressure in rats After the experiment (ie 28 days after intragastric administration), the rats were weighed and anesthetized by intraperitoneal injection of 10% chloral hydrate (purchased from Shenggong) (0.3mL/100g) After the rat enters anesthesia, the pulmonary artery pressure and right ventricular systolic pressure are measured.
- the measurement method refers to the standard operating procedures of the functional experimental system. The steps are as follows:
- the abdominal cavity of the rat was incised, the abdominal aorta was carefully separated, a 5ml syringe infiltrated with heparin sodium solution was used to point the needle at the proximal end of the abdominal aorta, and 3ml of aortic blood was slowly drawn and transferred to the anticoagulant blood collection tube.
- the blood gas analyzer measures the oxygen partial pressure (pO 2 ), carbon dioxide partial pressure (pCO 2 ), and blood oxygen saturation (SaO 2 ) indicators in the blood.
- Arterial partial pressure of oxygen reflects the oxygen uptake of pulmonary capillaries and is an indicator of respiratory conditions. It is the most sensitive indicator of whether the body is hypoxic. It is 80 ⁇ 110mmHg under normal conditions, and it is reflected when pO 2 is lower than 80mmHg The body is hypoxic. Arterial blood carbon dioxide partial pressure is an important indicator of respiratory acid-base balance disorder. When lung function is abnormal, insufficient ventilation, insufficient CO 2 excretion, etc., will cause its partial pressure to increase. It is respiratory acidosis. Under normal conditions It is 35 ⁇ 45mmHg.
- the oxygen saturation SaO 2 reflects the index as the percentage of the volume of oxygen-bound hemoglobin HbO2 in the blood to the total volume of hemoglobin Hb that can be bound. It is an important physiological parameter of the respiratory cycle. When the lung function is affected, hypoxia will occur, leading to blood Oxygen saturation decreases, and SaO 2 ⁇ 90% under normal conditions.
- RVI refers to the measurement of the right ventricular hypertrophy index in rats. The measurement results show that after administration intervention, the right ventricular hypertrophy index of each group has different changes. Among them, the RVI of the bosentan group decreased by 15.7% compared with the negative control group. Compared with the negative control group, the RVI of the tinib group was reduced by 17.8%, the 45mg/kg compound 1 high-dose group was reduced by 29.6% compared with the negative control group, and the 30mg/kg compound 1 middle-dose group was reduced by 9.4 compared with the negative control group. %, 15mg/kg compound 1 low-dose group compared with the negative control group RVI decreased by 5.5%.
- the 45mg/kg compound 1 high-dose group had no significant difference compared with the imatinib and bosentan groups, and there was a very significant difference compared with the other groups (p ⁇ 0.001).
Abstract
Description
GI 50(μM) | BaF3 | BaF3-tel-PDGFRβ | BaF3-tel-PDGFRα |
化合物1 | 4.081 | 0.43 | 0.056 |
化合物2 | 9.294 | 0.04 | 0.0028 |
化合物3 | 6.5 | 0.0014 | 0.0014 |
化合物4 | ~10 | 0.0032 | <0.0003 |
化合物5 | ~10 | <0.0003 | <0.0003 |
化合物6 | >10 | 0.001 | <0.0003 |
化合物7 | >10 | 0.001 | <0.0003 |
化合物8 | >10 | 0.0013 | |
化合物9 | >10 | <0.0003 | |
化合物10 | >10 | 0.062 | |
化合物11 | >10 | 0.0011 | |
化合物12 | ~10 | 0.001 | |
化合物13 | >10 | 0.0055 | 0.0016 |
化合物14 | 8.4 | <0.0015 | <0.0015 |
化合物15 | 3.9 | <0.0015 | <0.0015 |
化合物16 | >10 | <0.0015 | <0.0015 |
化合物17 | 2.8 | <0.0015 | <0.0015 |
化合物19 | >10 | <0.01 | <0.01 |
化合物20 | 5.07 | <0.01 | <0.01 |
化合物21 | 2.84 | <0.01 | <0.01 |
化合物22 | 0.96 | <0.01 | <0.01 |
化合物24 | 4.76 | <0.01 | <0.01 |
化合物25 | 5.55 | <0.01 | <0.01 |
化合物26 | 4.74 | <0.01 | <0.01 |
化合物27 | 4.73 | <0.01 | <0.01 |
化合物28 | 3.9 | <0.01 | <0.01 |
化合物29 | 2.84 | <0.01 | <0.01 |
化合物32 | 9.2 | <0.01 | <0.01 |
化合物33 | 6.49 | <0.01 | <0.01 |
化合物34 | >10 | <0.01 | <0.01 |
化合物35 | 5.84 | <0.01 | <0.01 |
化合物36 | 9.76 | <0.01 | <0.01 |
化合物37 | 9.85 | <0.01 | <0.01 |
化合物38 | >10 | <0.01 | <0.01 |
化合物39 | >10 | <0.01 | <0.01 |
化合物40 | 9.99 | <0.01 | <0.01 |
化合物41 | 3.66 | <0.01 | <0.01 |
化合物42 | >10 | <0.01 | <0.01 |
化合物43 | >10 | <0.01 | <0.01 |
GI 50(μM) | 化合物1 |
BaF3 | 4.081 |
BaF3-P210 | >10 |
BaF3-P210-T315I | 5.159 |
BaF3-FL-BRAF-V600E | 4.7 |
BaF3-TEL-cKIT | 5.343 |
BaF3-TEL-PDGFRβ | 0.43 |
BaF3-TEL-PDGFRα | 0.056 |
BaF3-TEL-VEGFR2 | 4 |
BaF3-TEL-FGFR2 | 3.256 |
Claims (15)
- 如权利要求1所述的PDGFR激酶抑制剂,其中R 3选自甲基、氟和氯。
- 如权利要求1-4中任一项所述的PDGFR激酶抑制剂,其中R 1取代基在吡啶环上N原子的对位或间位的碳上取代。
- 如权利要求1-4中任一项所述的PDGFR激酶抑制剂,其中所述杂环烷基选自吡咯烷基、吗啉基、哌嗪基、四氢吡喃基、四氢呋喃基、氧杂环丁烷基和氮杂环丁烷基,所述杂螺环烷基选自包括氧和/或氮杂原子的6-10元螺环烷基。
- 如权利要求1-4中任一项所述的PDGFR激酶抑制剂,其中R 1选自C 1-6烷基哌嗪基、吗啉基、四氢吡喃基C 1-6烷氧基、氧杂环丁烷基氧基、吗啉代C 1-6烷氧基、四氢呋喃基C 1-6烷氧基、C 3-6环烷基C 1-6烷氧基、和氧杂氮杂螺庚基。
- 如权利要求1-4中任一项所述的PDGFR激酶抑制剂,其中R 1选自N-甲基哌嗪-1-基、N-吗啉基、四氢吡喃-4-基甲氧基、氧杂环丁烷-3-基氧基、2-吗啉代乙氧基、四氢呋喃-2-基甲氧基、环戊基甲氧基、和2-氧杂-6-氮杂螺[3.3]庚-6-基。
- 一种药物组合物,其包括如权利要求1-9中任一项所述的PDGFR激酶抑制剂、和药学可接受的载体或赋形剂、以及任选的其它治疗剂。
- 如权利要求1-9中任一项所述的PDGFR激酶抑制剂,用于抑制PDGFRα和/或PDGFRβ活性的用途。
- 如权利要求1-9中任一项所述的PDGFR激酶抑制剂,用于治疗、预防或改善由PDGFRα和/或PDGFRβ活性调节的或者受其影响的或者其中涉及PDGFRα和/或PDGFRβ活性的疾病、障碍或病症的用途。
- 如权利要求12所述的PDGFR激酶抑制剂的用途,其中所述疾病、障碍或病症选自以下增殖性疾病:肺动脉高压、实体瘤、肉瘤、胃肠道间质瘤、结直肠癌、急性粒细胞白血病、慢性髓性白血病、甲 状腺癌、系统性肥大细胞病、嗜酸性粒细胞增多综合症、慢性嗜酸性粒细胞白血病、纤维变性、红斑狼疮、移植物抗宿主病、神经纤维瘤、肺高压、阿尔茨海默病、精原细胞瘤、无性细胞瘤、肥大细胞肿瘤、肺癌、支气管癌、睾丸上皮内瘤形成、黑色素瘤、乳腺癌、神经母细胞瘤、乳头状/滤泡型甲状腺癌、恶性淋巴瘤、非霍奇金淋巴瘤、2型多发性内分泌瘤形成、嗜铬细胞瘤、甲状腺癌、甲状旁腺增生/腺瘤、结肠癌、结肠直肠腺瘤、卵巢癌、前列腺癌、成胶质细胞瘤、脑肿瘤、恶性神经胶质瘤、胰腺癌、恶性胸膜间皮瘤、成血管细胞瘤、血管瘤、肾癌、肝癌、肾上腺癌、膀胱癌、胃癌、直肠癌、阴道癌、宫颈癌、子宫内膜癌、多发性骨髓瘤、颈和头部肿瘤、瘤形成、或其组合。
- 如权利要求12所述的PDGFR激酶抑制剂的用途,其中所述疾病、障碍或病症选自以下自身免疫性疾病:关节炎、风湿性关节炎、骨关节炎、狼疮、类风湿性关节炎、炎性肠病、银屑病性关节炎、斯蒂尔病、青少年关节炎、糖尿病、重症肌无力症、桥本甲状腺炎、奥德甲状腺炎、格雷夫斯病、类风湿性关节炎综合征、多发性硬化症、传染性神经元炎、急性播散性脑脊髓炎、阿狄森病、视性眼阵孪-肌阵孪综合征、强直性脊椎炎、抗磷脂抗体综合征、再生障碍性贫血、自身免疫性肝炎、乳糜泻、古德帕斯彻综合征、特发性血小板减少性紫癜、视神经炎、硬皮病、原发性胆汁性肝硬化、莱特尔综合征、高安动脉炎、颞动脉炎、温型自身免疫性溶血性贫血、韦格纳肉芽肿病、银屑病、全身脱毛、贝赫切特病、慢性疲劳、家族性自主神经功能异常、子宫内膜异位、间质性膀胱炎、神经肌强直、硬皮病、外阴痛、或其组合。
- 如权利要求12所述的PDGFR激酶抑制剂的用途,其中所述疾病、障碍或病症为肺动脉高压、慢性嗜酸性粒细胞白血病、或其组合。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3147649A CA3147649A1 (en) | 2019-08-29 | 2020-08-14 | Pyrazole derivatives and use thereof |
MX2022002000A MX2022002000A (es) | 2019-08-29 | 2020-08-14 | Derivados de pirazol y uso de los mismos. |
KR1020227010519A KR20220054848A (ko) | 2019-08-29 | 2020-08-14 | 피라졸 유도체 및 이의 용도 |
EP20858009.2A EP4023643A4 (en) | 2019-08-29 | 2020-08-14 | PYRAZOLE DERIVATIVE AND USE THEREOF |
AU2020338637A AU2020338637B2 (en) | 2019-08-29 | 2020-08-14 | Pyrazole derivative and use thereof |
JP2022513158A JP7356580B2 (ja) | 2019-08-29 | 2020-08-14 | ピラゾール誘導体及びその使用 |
US17/637,860 US20220288064A1 (en) | 2019-08-29 | 2020-08-14 | Pyrazole derivatives and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910807395 | 2019-08-29 | ||
CN201910807395.9 | 2019-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021036814A1 true WO2021036814A1 (zh) | 2021-03-04 |
Family
ID=74684958
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/104526 WO2021035788A1 (zh) | 2019-08-29 | 2019-09-05 | 吡唑衍生物及其用途 |
PCT/CN2020/109130 WO2021036814A1 (zh) | 2019-08-29 | 2020-08-14 | 吡唑衍生物及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/104526 WO2021035788A1 (zh) | 2019-08-29 | 2019-09-05 | 吡唑衍生物及其用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220288064A1 (zh) |
EP (1) | EP4023643A4 (zh) |
JP (1) | JP7356580B2 (zh) |
KR (1) | KR20220054848A (zh) |
CN (1) | CN112442014B (zh) |
AU (1) | AU2020338637B2 (zh) |
CA (1) | CA3147649A1 (zh) |
MX (1) | MX2022002000A (zh) |
WO (2) | WO2021035788A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022188792A1 (zh) * | 2021-03-12 | 2022-09-15 | 四川科伦博泰生物医药股份有限公司 | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7531560B2 (en) * | 2004-11-10 | 2009-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
CN101501023A (zh) * | 2006-07-07 | 2009-08-05 | 贝林格尔.英格海姆国际有限公司 | 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途 |
WO2011117381A1 (en) * | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008106202A1 (en) * | 2007-02-27 | 2008-09-04 | Housey Gerard M | Theramutein modulators |
CN103539784B (zh) * | 2012-07-09 | 2016-08-17 | 中国科学院广州生物医药与健康研究院 | 杂环苯甲酰胺类化合物、药用组合物及其应用 |
CN104844566B (zh) * | 2014-12-12 | 2018-05-18 | 合肥中科普瑞昇生物医药科技有限公司 | 一种新型结构的激酶抑制剂 |
CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
CN107805240A (zh) * | 2016-09-08 | 2018-03-16 | 中国科学院合肥物质科学研究院 | 一种新型的pdgfr激酶抑制剂及其用途 |
CN108368060B (zh) * | 2017-12-21 | 2020-09-15 | 中国科学院合肥物质科学研究院 | 一类嘧啶类衍生物激酶抑制剂 |
-
2019
- 2019-09-05 WO PCT/CN2019/104526 patent/WO2021035788A1/zh active Application Filing
-
2020
- 2020-08-14 EP EP20858009.2A patent/EP4023643A4/en active Pending
- 2020-08-14 CN CN202010816805.9A patent/CN112442014B/zh active Active
- 2020-08-14 KR KR1020227010519A patent/KR20220054848A/ko active Search and Examination
- 2020-08-14 JP JP2022513158A patent/JP7356580B2/ja active Active
- 2020-08-14 CA CA3147649A patent/CA3147649A1/en active Pending
- 2020-08-14 US US17/637,860 patent/US20220288064A1/en active Pending
- 2020-08-14 MX MX2022002000A patent/MX2022002000A/es unknown
- 2020-08-14 AU AU2020338637A patent/AU2020338637B2/en active Active
- 2020-08-14 WO PCT/CN2020/109130 patent/WO2021036814A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7531560B2 (en) * | 2004-11-10 | 2009-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
CN101501023A (zh) * | 2006-07-07 | 2009-08-05 | 贝林格尔.英格海姆国际有限公司 | 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途 |
WO2011117381A1 (en) * | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
Non-Patent Citations (7)
Title |
---|
"The Pharmacological Basis of Therapeutics", 1996, MCGRAW-HILL |
BETSHOLTZ, C. ET AL., BIOESSAYS, vol. 23, 2001, pages 494 - 507 |
COOLS J.DEANGELO D.J.GOTLIB J.: "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome", N. ENGL. J. MED., vol. 348, no. 13, 2003, pages 1201 - 14, XP009071542, DOI: 10.1056/NEJMoa025217 |
LI DAIHONG, AI JUNTAO, XIE XIN, HU GAOYUN, LI QIANBIN: "Research Progress on Platelet-derived Growth Factor Receptor Inhibitors", ANTI-TUMOR PHARMACY, vol. 3, no. 1, 28 February 2013 (2013-02-28), pages 2 - 6+21, XP055955342, ISSN: 2095-1264, DOI: 10.3969/j.issn.2095-1264.2013.001 * |
SANDY, J. R., BR. J. ORTHOD., vol. 25, 1998, pages 269 - 74 |
SCHALLER, J. L.BURKLAND, G. A.: "Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate", MEDGENMED, vol. 3, no. 5, 2001, pages 9, XP009535335 |
SCHERMULY, R.T. ET AL.: "Reversal of experimental pulmonary hypertension by PDGF inhibition", J. CLIN. INVEST., vol. 115, 2005, pages 2811 - 2821, XP008056354, DOI: 10.1172/JCI24838 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022188792A1 (zh) * | 2021-03-12 | 2022-09-15 | 四川科伦博泰生物医药股份有限公司 | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2022546409A (ja) | 2022-11-04 |
MX2022002000A (es) | 2022-04-25 |
WO2021035788A1 (zh) | 2021-03-04 |
CA3147649A1 (en) | 2021-03-04 |
EP4023643A1 (en) | 2022-07-06 |
CN112442014B (zh) | 2021-10-08 |
US20220288064A1 (en) | 2022-09-15 |
KR20220054848A (ko) | 2022-05-03 |
AU2020338637A1 (en) | 2022-03-10 |
EP4023643A4 (en) | 2023-09-06 |
CN112442014A (zh) | 2021-03-05 |
AU2020338637B2 (en) | 2023-04-13 |
JP7356580B2 (ja) | 2023-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10793543B2 (en) | Selective C-KIT kinase inhibitor | |
RU2656591C2 (ru) | Модуляторы протеин-тирозинкиназы и способы их применения | |
JP2018515569A (ja) | キナーゼを調節するための化合物の固体形態 | |
TW201201803A (en) | Chemical compounds | |
CN102171214A (zh) | 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 | |
EP2581371B1 (en) | Pyrrolyl substituted dihydroindol-2-one derivatives, preparation methods and uses thereof | |
BR112021005750A2 (pt) | inibidor de fgfr4 e uso do mesmo | |
WO2021036814A1 (zh) | 吡唑衍生物及其用途 | |
CN111606887B (zh) | 一种新型激酶抑制剂 | |
CN111303024B (zh) | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 | |
TW201504239A (zh) | 蛋白酪氨酸激酶抑制劑及其應用 | |
US20150353524A1 (en) | Pyridine compounds used as pi3 kinase inhibitors | |
RU2805207C1 (ru) | Производные пиразола и их применение | |
WO2014086102A1 (zh) | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 | |
CN110283160B (zh) | 一种pdgfr激酶抑制剂 | |
CN111138426B (zh) | 吲唑类激酶抑制剂及其用途 | |
RU2792626C1 (ru) | Новый ингибитор киназы pan-raf и его применение | |
WO2023245015A2 (en) | Phenyl amide compounds and methods of use | |
WO2023150291A2 (en) | Heterocyclic compounds and methods of use | |
CN115894486A (zh) | 一种氢化吡啶并喹唑啉类化合物、组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20858009 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3147649 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022513158 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020338637 Country of ref document: AU Date of ref document: 20200814 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227010519 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020858009 Country of ref document: EP Effective date: 20220329 |